Current stage-Stage IV (Advanced) Posts on Medivizor
Navigation Menu

Current stage-Stage IV (Advanced) Posts on Medivizor

Searching for patients with unresponsive cancer to test a new treatment

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers.  The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...

Read More

Nivolumab plus AVD chemotherapy for patients with advanced classical Hodgkin lymphoma

Posted by on Jun 16, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study assessed the effectiveness of nivolumab (Opdivo) alone or with chemotherapy for patients with advanced classical Hodgkin lymphoma (cHL). This study concluded that nivolumab plus chemotherapy was promising, with manageable side effects for these patients. Some background Standard first-line chemotherapy is highly effective...

Read More

Searching for children with advanced Hodgkin lymphoma to test a new chemoimmunotherapy combination regimen

Posted by on May 24, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is evaluating the effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for children with advanced Hodgkin lymphoma (HL). The main outcome to be measured will be the number of patients who respond to treatment. The details Brentuximab vedotin is being tested to treat children who have advanced HL. Brentuximab...

Read More

Evaluating scoring systems used to predict outcomes for patients with advanced HL

Posted by on Apr 24, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of the International Prognostic Scoring System (IPSS) measuring 7 factors (IPSS7) versus the IPSS measuring 3 factors (IPSS3) in predicting outcomes for patients with Hodgkin's lymphoma (HL). This study concluded that there was no significant difference between these scoring systems. Some...

Read More

Evaluating the long-term outcomes of Zevalin for patients with advanced B cell lymphoma

Posted by on Jan 10, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...

Read More

Evaluating intensive first-line treatment for patients with advanced Hodgkin’s lymphoma

Posted by on Nov 27, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with advanced Hodgkin’s lymphoma (HL) who received intensive first-line treatment. This study concluded that intensive first-line treatment with or without radiotherapy led to better long-term outcomes in these patients. Some background For patients with advanced HL,...

Read More

Long-term outcomes of radioimmunotherapy in patients with follicular lymphoma

Posted by on Oct 5, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...

Read More

Comparing obinutuzumab and rituximab in first-line chemotherapy regimens for follicular lymphoma

Posted by on Jul 2, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...

Read More

What are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?

Posted by on Feb 9, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...

Read More

Does biosimilar filgrastim improve neutropenia in older DLBCL patients receiving chemotherapy?

Posted by on Dec 20, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the outcomes of older patients with stage 3 or 4 DLBCL (diffuse large B-cell lymphoma) who received biosimilar filgrastim (Neupogen) during their chemotherapy. The study concluded that filgrastim was safe and effective in these patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type...

Read More

Is changing treatment intensity after PET scan effective for patients with advanced stage Hodgkin lymphoma?

Posted by on Dec 6, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at changing treatment intensity after a PET scan for patients with advanced stage Hodgkin lymphoma. The authors concluded that reducing treatment intensity for patients with a negative PET scan can reduce negative side effects and improve long-term outcomes. Some background Advanced stage Hodgkin lymphoma (HL) can...

Read More

Comparison between rituximab and CT-P10 biosimilar medication for the treatment of patients with advanced stage follicular lymphoma

Posted by on Oct 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared rituximab (Rituxan) and CT-P10 treatments for patients with previously untreated advanced stage follicular lymphoma. The study concluded that CT-P10 is just as safe and effective as name-brand rituximab.  Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is commonly treated...

Read More